Abstract
Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 599-603 |
| Number of pages | 5 |
| Journal | Hepato-Gastroenterology |
| Volume | 58 |
| Issue number | 106 |
| Publication status | Published - Mar 2011 |
Fingerprint
Keywords
- GEMOX
- Locally advanced pancreatic cancer
- Neoadjuvant therapy
- Radiotherapy
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
Cite this
GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer. / Milandri, Carlo; Polico, Rolando; Garcea, Domenico; Passardi, Alessando; Gardini, Andrea; Romeo, Antonino; Scarpi, Emanuela; Rosetti, Paola; Ridolfi, Laura; La Barba, Giuliano; Ricci, Marianna; Amadori, Dino.
In: Hepato-Gastroenterology, Vol. 58, No. 106, 03.2011, p. 599-603.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer
AU - Milandri, Carlo
AU - Polico, Rolando
AU - Garcea, Domenico
AU - Passardi, Alessando
AU - Gardini, Andrea
AU - Romeo, Antonino
AU - Scarpi, Emanuela
AU - Rosetti, Paola
AU - Ridolfi, Laura
AU - La Barba, Giuliano
AU - Ricci, Marianna
AU - Amadori, Dino
PY - 2011/3
Y1 - 2011/3
N2 - Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.
AB - Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.
KW - GEMOX
KW - Locally advanced pancreatic cancer
KW - Neoadjuvant therapy
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=79958165537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958165537&partnerID=8YFLogxK
M3 - Article
C2 - 21661438
AN - SCOPUS:79958165537
VL - 58
SP - 599
EP - 603
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 106
ER -